Pharmidex to partner on Innovate UK Grant focusing on Multiple Sclerosis
May 23, 2017

Proud to partner in developing novel therapies for Multiple Sclerosis

Pharmidex are proud to partner in developing novel therapies for Multiple Sclerosis as part of a new Innovate UK accepted grant.

This new Venture plans to fight Multiple Sclerosis through ‘NanoMedicine’, which is supported by Cambridge Judge Business School.


The grant itself has been funded £1 million new funding to explore this dieases area. Of the £1 million funding receieved more than £828,000 will be through the government’s Innovate UK BioMedical Catalyst Competition awarded to LIFNanoRx – which has brought together a project team that includes Pharmidex; the University of London’s Blizard Institute – a world-renowned center for treatment of MS; and the Government’s Center for Process Innovation. 



You can find more information on the following website: http://www.epe.admin.cam.ac.uk/grant-lifnanorx

We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist

We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist

July 30, 2025
We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist

🎓 Welcoming Future Scientists to Pharmidex! 🎓

July 28, 2025
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. 👩‍🔬 👨‍🔬 Welcome to the team, Gabrielle and Mohammed!
BATA Taste Aversion

Does your compound taste good enough for the clinic?

July 24, 2025
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: ✅ Bitter-tasting APIs ✅ Unpalatable excipients ✅ The success of taste-masking strategies ✅ Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
More Posts